Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Levamisole | hsa00250 | Alanine, aspartate and glutamate metabolism | 1.22E-02 | 2 | Q96RQ9, P15104 | IL4I1, GLUL | More | | Levamisole | hsa00270 | Cysteine and methionine metabolism | 3.39E-02 | 2 | Q96RQ9, P40926 | IL4I1, MDH2 | More | | Levamisole | hsa00330 | Arginine and proline metabolism | 4.40E-02 | 1 | P17707 | AMD1 | More | | Levamisole | hsa00440 | Phosphonate and phosphinate metabolism | 4.40E-02 | 1 | Q9Y6K0 | CEPT1 | More | | Levamisole | hsa00500 | Starch and sucrose metabolism | 1.34E-02 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Levamisole | hsa00561 | Glycerolipid metabolism | 1.12E-02 | 3 | Q8NEB5, P14550, Q86XP1 | PPAPDC1B, AKR1A1, DGKH | More | | Levamisole | hsa00730 | Thiamine metabolism | 3.83E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Levamisole | hsa00740 | Riboflavin metabolism | 4.40E-02 | 1 | Q969G6 | RFK | More | | Levamisole | hsa00830 | Retinol metabolism | 4.40E-02 | 1 | P00325 | ADH1B | More | | Levamisole | hsa00900 | Terpenoid backbone biosynthesis | 1.22E-02 | 2 | P49354, Q9UHG3 | FNTA, PCYOX1 | More | | Levamisole | hsa04020 | Calcium signaling pathway | 2.41E-02 | 5 | Q96DU7, Q13557, P21860, P26678, P63092 | ITPKC, CAMK2D, ERBB3, PLN, GNAS | More | | Levamisole | hsa04114 | Oocyte meiosis | 1.33E-02 | 4 | P51812, Q02750, P16298, Q17RY0 | RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Levamisole | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Levamisole | hsa04330 | Notch signaling pathway | 1.12E-02 | 3 | Q92542, P49768, P46531 | NCSTN, PSEN1, NOTCH1 | More | | Levamisole | hsa04370 | VEGF signaling pathway | 2.68E-03 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Levamisole | hsa04610 | Complement and coagulation cascades | 1.06E-02 | 1 | P0C0L4 | C4A | More | | Levamisole | hsa04622 | RIG-I-like receptor signaling pathway | 3.39E-02 | 2 | Q12933, P10145 | TRAF2, IL8 | More | | Levamisole | hsa04650 | Natural killer cell mediated cytotoxicity | 3.18E-03 | 9 | P16298, P50591, P78314, P06239, O60880, P20963, Q02750, P26718, O75015 | PPP3CB, TNFSF10, SH3BP2, LCK, SH2D1A, CD247, MAP2K1, KLRK1, FCGR3B | More | | Levamisole | hsa04658 | Th1 and Th2 cell differentiation | 9.73E-03 | 6 | P20963, P09693, Q16539, P06239, Q9UL17, P13765 | CD247, CD3G, MAPK14, LCK, TBX21, HLA-DOB | More | | Levamisole | hsa04659 | Th17 cell differentiation | 7.42E-03 | 7 | Q16539, P06239, P13765, P14778, Q9UL17, P09693, P20963 | MAPK14, LCK, HLA-DOB, IL1R1, TBX21, CD3G, CD247 | More | | Levamisole | hsa04713 | Circadian entrainment | 1.75E-02 | 4 | Q13557, Q02153, P61952, P63092 | CAMK2D, GUCY1B3, GNG11, GNAS | More | | Levamisole | hsa04720 | Long-term potentiation | 1.38E-02 | 3 | P16298, P51812, Q02750 | PPP3CB, RPS6KA3, MAP2K1 | More | | Levamisole | hsa04728 | Dopaminergic synapse | 2.41E-02 | 5 | P63092, P61952, Q99941, Q13557, O15516 | GNAS, GNG11, CREBL1, CAMK2D, CLOCK | More | | Levamisole | hsa04911 | Insulin secretion | 4.88E-02 | 3 | P63092, Q99941, Q13557 | GNAS, CREBL1, CAMK2D | More | | Levamisole | hsa04914 | Progesterone-mediated oocyte maturation | 2.94E-02 | 3 | Q17RY0, P51812, Q02750 | CPEB4, RPS6KA3, MAP2K1 | More | | Levamisole | hsa04934 | Cushing syndrome | 1.75E-02 | 4 | Q99941, P63092, O15169, Q13557 | CREBL1, GNAS, AXIN1, CAMK2D | More | | Levamisole | hsa05031 | Amphetamine addiction | 4.88E-02 | 3 | Q13557, P63092, Q99941 | CAMK2D, GNAS, CREBL1 | More | | Levamisole | hsa05144 | Malaria | 1.44E-02 | 4 | P60033, O60603, P35443, P26718 | CD81, TLR2, THBS4, KLRK1 | More | | Levamisole | hsa05150 | Staphylococcus aureus infection | 2.01E-02 | 2 | P0C0L4, P20036 | C4A, HLA-DPA1 | More | | Levamisole | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 1.94E-02 | 4 | P62879, P16298, Q02750, P0CG47 | GNB2, PPP3CB, MAP2K1, UBB | More | | Levamisole | hsa05169 | Epstein-Barr virus infection | 4.41E-02 | 8 | P13765, Q13547, O00463, Q16539, P24522, O60603, P09693, P20963 | HLA-DOB, HDAC1, TRAF5, MAPK14, GADD45A, TLR2, CD3G, CD247 | More | | Levamisole | hsa05170 | Human immunodeficiency virus 1 infection | 6.02E-03 | 5 | Q02750, P62879, P16298, Q05397, P20333 | MAP2K1, GNB2, PPP3CB, PTK2, TNFRSF1B | More | | Levamisole | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Levamisole | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Levamisole | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.03E-02 | 5 | P20963, P09693, P06239, O60603, Q16539 | CD247, CD3G, LCK, TLR2, MAPK14 | More | | Levamisole | hsa05322 | Systemic lupus erythematosus | 2.92E-02 | 2 | P0C0L4, P20036 | C4A, HLA-DPA1 | More | | |